title: Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
authors.forename: Ida
authors.initials: I
authors.lastname: Iurisci
authors.forename: Tyvin
authors.initials: T
authors.lastname: Rich
authors.forename: Francis
authors.initials: F
authors.lastname: Lévi
authors.forename: Pasquale F
authors.initials: PF
authors.lastname: Innominato
authors.forename: Nicola
authors.initials: N
authors.lastname: Tinari
authors.forename: Luciana
authors.initials: L
authors.lastname: Irtelli
authors.forename: Michele
authors.initials: M
authors.lastname: De Tursi
authors.forename: Antonino
authors.initials: A
authors.lastname: Grassadonia
authors.forename: Stefano
authors.initials: S
authors.lastname: Iacobelli
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D002940:Circadian Rhythm; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011788:Quality of Life; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib